Print this page
-
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Applicable Disease Sites: Liver
-
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
Prospective Evaluation and Validation of AI-Enhanced Ultrasound Imaging for Early Detection of Liver Disease
Protocol: 002571Applicable Disease Sites: Liver
Other -
Preoperative Plasma ctDNA Detection in Early Stage Cancer: A Proof-of-Concept Evaluation
Protocol: 032308Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Colon
Lung -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Pancreas -
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.
Protocol: 072201Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE).
Protocol: 072204Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Esophagus
Stomach -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Understanding the Role of Pepsinogen and Gut Microbiome as a Biomarker of Cancer in the Gastrointestinal Tract.
Protocol: 072208Principal Investigator:
- Haejin In
Applicable Disease Sites: Stomach -
Pilot Study of Stomach Cancer Early Detection and Prevention with Endoscopy (Pilot-SCREEN).
Protocol: 072211Principal Investigator:
- Haejin In
Applicable Disease Sites: Stomach -
Pilot of Streamlined Follow-up Pathway for Patients with Potential Gastrointestinal Cancer Identified in the Emergency Department: Baseline Metrics, Acceptance and Feasibility
Protocol: 072302Applicable Disease Sites: Colon